IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Fiduciary Trust Co

Fiduciary Trust Co lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.4% during the third quarter, Holdings Channel.com reports. The firm owned 8,885 shares of the company’s stock after selling 4,666 shares during the quarter. Fiduciary Trust Co’s holdings in IDEXX Laboratories were worth $4,489,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC boosted its holdings in IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock valued at $340,000 after purchasing an additional 96 shares in the last quarter. Manning & Napier Advisors LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at approximately $20,418,000. Oppenheimer Asset Management Inc. boosted its holdings in IDEXX Laboratories by 13.8% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after purchasing an additional 1,453 shares in the last quarter. National Pension Service boosted its holdings in IDEXX Laboratories by 7.3% in the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after purchasing an additional 12,647 shares in the last quarter. Finally, EFG Asset Management Americas Corp. boosted its holdings in IDEXX Laboratories by 45.3% in the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company’s stock valued at $6,201,000 after purchasing an additional 3,966 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.1 %

Shares of IDEXX Laboratories stock opened at $421.76 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a market capitalization of $34.54 billion, a P/E ratio of 40.67, a P/E/G ratio of 3.68 and a beta of 1.36. The business has a 50 day moving average price of $453.61 and a 200 day moving average price of $478.67.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.53 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of several research analyst reports. Piper Sandler reissued a “neutral” rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Barclays decreased their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Stifel Nicolaus decreased their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.